ProfileGDS4814 / ILMN_1685319
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 20% 23% 20% 8% 8% 6% 2% 20% 18% 22% 10% 13% 9% 35% 21% 25% 6% 6% 12% 18% 28% 3% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)43.611520
GSM780708Untreated after 4 days (C2_1)44.109823
GSM780709Untreated after 4 days (C3_1)43.455120
GSM780719Untreated after 4 days (C1_2)40.39958
GSM780720Untreated after 4 days (C2_2)40.62728
GSM780721Untreated after 4 days (C3_2)40.01826
GSM780710Trastuzumab treated after 4 days (T1_1)37.73282
GSM780711Trastuzumab treated after 4 days (T2_1)43.547120
GSM780712Trastuzumab treated after 4 days (T3_1)43.138218
GSM780722Trastuzumab treated after 4 days (T1_2)44.057522
GSM780723Trastuzumab treated after 4 days (T2_2)41.17410
GSM780724Trastuzumab treated after 4 days (T3_2)42.053813
GSM780713Pertuzumab treated after 4 days (P1_1)40.90169
GSM780714Pertuzumab treated after 4 days (P2_1)46.596835
GSM780715Pertuzumab treated after 4 days (P3_1)43.842721
GSM780725Pertuzumab treated after 4 days (P1_2)44.500925
GSM780726Pertuzumab treated after 4 days (P2_2)39.79046
GSM780727Pertuzumab treated after 4 days (P3_2)39.97886
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)41.739112
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)43.032718
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)45.101228
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)38.57123
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)46.043232